International Journal of Cancer最新文献

{"title":"Socioeconomic differences among patients with stage I-III colon cancer: Detection, treatment and relative survival.","authors":"Felice N van Erning, Laskarina J K Galanos, Robin Lurvink, Mieke J Aarts, Irene E G van Hellemond, Iris D Nagtegaal, Ignace H J T de Hingh, Johannes H W de Wilt, Marloes A G Elferink","doi":"10.1002/ijc.70181","DOIUrl":"https://doi.org/10.1002/ijc.70181","url":null,"abstract":"<p><p>Colon cancer is a significant public health concern. Several risk factors for colon cancer are strongly associated with socioeconomic position (SEP). This study investigates associations between SEP and screening versus clinical detection, treatment characteristics, and relative survival. Patients with stage I-III colon cancer diagnosed between 2015 and 2023 were selected from the Netherlands Cancer Registry. SEP was based on household income at postal code level. Associations between SEP and screening versus clinical detection and treatment characteristics were assessed using multivariable logistic regression analyses. Crude 5-year relative survival by SEP was calculated, and relative excess risks of death were assessed using a multivariable generalized linear model. The total study population consisted of 62,412 patients. Most prominently, compared to patients with lower SEP, patients with intermediate or higher SEP were more often diagnosed through screening (23% vs. 31% and 33%, p <.0001), more often received adjuvant chemotherapy in stage III (53% vs. 64% and 68%, p <.0001), and less often had an adverse hospital course (54% vs. 47% and 44%, p <.0001). Crude 5-year relative survival was 86.0% for lower, 87.5% for intermediate, and 88.7% for higher SEP (intermediate versus lower SEP: adjusted RER 0.97, 95% CI 0.90-1.03; higher versus lower SEP: adjusted RER 0.89, 95% CI 0.83-0.95). Patients with intermediate or higher SEP were more often diagnosed through screening and had several favorable treatment characteristics compared to patients with lower SEP. For higher versus lower SEP, this translated into a small survival advantage, even after adjustment for patient, tumor, and treatment characteristics.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated scFv identification and CAR T cell generation for AML targeting in vivo.","authors":"Yi Liu, Annika Lauk, David Sedloev, Josephine Brysting, Ela Cetin, Chunan Liu, Maximilian Mönnig, Thomas Luft, Haiyang Yun, Michael Schmitt, Tim Sauer, Fengbiao Zhou, Christian Rohde, Carsten Müller-Tidow","doi":"10.1002/ijc.70146","DOIUrl":"https://doi.org/10.1002/ijc.70146","url":null,"abstract":"<p><p>Cancer immunotherapy has witnessed remarkable advancements, particularly in the development of chimeric antigen receptor (CAR) T cell therapy. Here, we integrated single chain variable fragment (scFv) development with CAR T cell generation based on a newly developed scFv phagemid library. High-throughput long-read PacBio sequencing identified 4.5 × 10⁷ unique full-length scFv proteins within the generated library. As a proof of principle, we screened for scFvs targeting C-type lectin-like molecule-1 (CLL1) with subsequent cloning into a third generation retroviral CAR backbone. Functional assays revealed the specificity and potency of these CAR T cells in targeting CLL1-positive AML cells in vitro. In vivo studies reduced tumor burden and improved survival rates compared to controls. Taken together, screening for tumor-specific scFvs against CLL1 can rapidly generate AML-specific CAR T cells with effective tumor killing in vivo.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term cardiac outcomes in breast cancer patients treated with helical tomotherapy: Evaluating the applicability of 3D-based dose constraints for intensity modulated radiation therapy.","authors":"Pierre Loap, Abdelkarim Uakkas, Jihane Bouziane, Alain Fourquet, Youlia Kirova","doi":"10.1002/ijc.35474","DOIUrl":"10.1002/ijc.35474","url":null,"abstract":"<p><p>Adjuvant breast radiotherapy has been associated with cardiac toxicity due to older 2D and 3D techniques, with a linear relationship between mean heart dose (MHD) and ischemic cardiac events. Cardiac dose distribution differs with modern techniques like intensity-modulated radiotherapy (IMRT), potentially affecting this relationship. This study evaluates long-term cardiac toxicity in breast cancer patients treated with tomotherapy to reassess 3D-derived dose constraints. Breast cancer patients treated with tomotherapy at Institut Curie from August 2010 to December 2015 were included. Patients had undergone breast-conserving surgery or mastectomy, with some receiving chemotherapy or trastuzumab. Tomotherapy was used for anatomically challenging cases. The primary endpoint was cardiac toxicity correlated with MHD; secondary endpoints were overall and disease-specific survival. Statistical analyses included logistic regression and Cox models. Among 179 patients, the median MHD was 7.04 Gy, with 95.6% having an MHD above 5 Gy. Sixty-six patients had cardiovascular risk factors, and 28.5% were obese. Over a median follow-up of 9.1 years, eight patients (4.5%) experienced cardiovascular events-all with pre-existing risks or obesity. No significant correlation was found between MHD and major coronary events (p = 0.607) or heart failure (p = 0.800). Cardiac mortality was absent, and 10-year overall and disease-specific survival were 88.0% and 94.3%, respectively. Cardiac events in patients treated with tomotherapy were rare and driven by pre-existing risk factors. The linear MHD-toxicity relationship observed in 3D radiotherapy may not apply to IMRT, potentially leading to overestimated risks. Long-term studies are needed to refine IMRT dose constraints.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"1386-1394"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"p16^INK4a and HPV E4 immunohistochemistry for the prediction of regression of cervical intraepithelial neoplasia grade 2-A historical cohort study.","authors":"Rikke Damgaard, David Jenkins, Mark H Stoler, Miekel van de Sandt, Maurits N C de Koning, Wim G V Quint, Johnny Kahlert, Patti E Gravitt, Torben Steiniche, Lone K Petersen, Anne Hammer","doi":"10.1002/ijc.35469","DOIUrl":"10.1002/ijc.35469","url":null,"abstract":"<p><p>Cervical intraepithelial neoplasia grade 2 (CIN2) is a heterogeneous diagnosis with a high likelihood of spontaneous regression. Therefore, active surveillance for CIN2 has been implemented as an option in younger women in many countries. Yet, little is known about markers that may accurately predict the likelihood of regression to support active surveillance. Here, we aimed to assess whether p16^INK4a and HPV E4 status are associated with the likelihood of CIN2 regression. We conducted a historical cohort study on women aged 23-40 diagnosed with untreated CIN2 following cytology-based screening. Women were diagnosed at Aarhus University Hospital, Denmark from January 2000 to December 2010. Archived tissue samples were sectioned for p16^INK4a and HPV E4 immunohistochemistry and HPV genotyping. We used a modified Poisson model to estimate the relative risk of regression, adjusting for age and cytology (aRR). A total of 443 women with CIN2 were included. Most women (73.8%) were aged ≤30, and half had a high-grade cytology (48.8%). Overall, 47.6% regressed, and regression was less likely in p16^INK4a-positive compared to p16^INK4a-negative women (aRR 0.77; 95% CI 0.64-0.94). Among p16^INK4a-positive women, the risk of regression varied by HPV type and HPVE4 status, with lower risk in HPV16-positive women compared to those without (aRR 0.54; 95% CI 0.40-0.75) and in HPVE4-negative compared to HPVE4 positive women (aRR 0.73; 95% CI 0.54-0.98). When we restricted to expert-confirmed CIN2, the risk of regression did not vary by p16^INK4a or HPVE4 status, while HPV16 positive remained at a lower risk of regression compared to women without HPV16.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"1294-1303"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between prediagnostic serum metabolites and pancreatic ductal adenocarcinoma risk in two prospective cohorts.","authors":"Ting Zhang, Steven C Moore, Sheng Fu, Xiaoyu Wang, Demetrius Albanes, Stephanie J Weinstein, Kai Yu, Rachael Z Stolzenberg-Solomon","doi":"10.1002/ijc.35479","DOIUrl":"10.1002/ijc.35479","url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma (PDAC) is highly fatal, with incidence rising worldwide. Metabolomics may provide insight into etiology and mechanisms contributing to pancreatic carcinogenesis. We examined associations between 1483 prediagnostic (up to 24 years) serum metabolites and PDAC in nested case-control studies within a cohort of male Finnish smokers and another of American men and women (n = 732 matched pairs). We used conditional logistic regression to calculate odds ratios (OR) and 95% confidence intervals per standard deviation increase in log-metabolite level within each cohort and combined using fixed-effect meta-analyses. We performed elastic net regression (EN) to select metabolites and calculated area under the curve (AUC) for established PDAC risk factors (smoking, diabetes, and overweight/obesity), selected metabolites, and their combination. Sixty-six metabolites were associated with PDAC at false discovery rate <0.05, with 26 below Bonferroni threshold (p < 3.4 × 10^-5) and 38 not reported previously. Notable findings include fibrinopeptide B (1-9); 13 modified, di- or poly-peptides; 11 tobacco-chemical related xenobiotics; glycolysis-gluconeogenesis-tricarboxylic acid (TCA) cycle metabolites (aspartate, glutamate, lactate, α-ketoglutarate, and pyruvate); and four secondary and two primary bile acids that were positively (OR = 1.18-1.58) and five fibrinogen cleavage peptides that were inversely (OR = 0.70-0.84) associated with PDAC. AUCs for combined metabolites-risk factors outperformed known risk factors (p ≤ .01) but not metabolites (p ≥ .31) alone. Systemic metabolism is prospectively associated with PDAC. New metabolite associations include those related to immune response, tobacco, microbiome, glycolysis-gluconeogenesis and TCA cycle, and adiposity or diabetes. The EN selected metabolites were more sensitive indicators of prediagnostic metabolic processes and exposures associated with PDAC than established risk factors.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"1304-1315"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The perioperative outcomes of retroperitoneal lymph node dissection in Germany for patients with testicular cancer: Results from the GRAND study.","authors":"Nikolaos Pyrgidis, Maria Apfelbeck, Marc Kidess, Philipp Weinhold, Julian Marcon, Gerald B Schulz, Yannic Volz, Benedikt Ebner, Peter Maximilian Sparwasser, Igor Tsaur, Marcus Hentrich, Christian G Stief, Michael Chaloupka","doi":"10.1002/ijc.35486","DOIUrl":"10.1002/ijc.35486","url":null,"abstract":"<p><p>We aimed to assess the current trends and outcomes of retroperitoneal lymph node dissection (RPLND) in patients with testicular cancer in Germany, as well as to provide evidence on the role of the type of surgical approach, prior chemotherapy, and annual hospital caseload. We used the GeRmAn Nationwide inpatient Data, provided by the Research Data Center of the Federal Bureau of Statistics (2005-2022). We assessed trends and perioperative outcomes (mortality, intensive care unit [ICU] admission, transfusion, acute embolism, and length of hospital stay) based on the surgical approach (robotic, laparoscopic, and open), prior chemotherapy, and annual hospital caseload (with cut-offs of three and 10 cases/year) with a multivariable regression analysis. Overall, 6673 patients underwent RPLND for testicular cancer. Of them, 5570 (83%) received open, 819 (12%) laparoscopic, and 284 (5%) robot-assisted surgery. Patients had previously received chemotherapy in 1908 (29%) cases. Accordingly, 4431 (66%) patients underwent surgery in centers performing more than 3 cases/year, and 1325 (20%) in centers performing more than 10 cases/year. Over the past 18 years, the number of patients undergoing RPLND has decreased by half. In the multivariate regression analysis, a robotic and a laparoscopic approach was associated with lower odds of ICU admission, transfusion, and shorter hospital stay (p < .001) compared to an open approach. Patients undergoing surgery after prior chemotherapy presented similar perioperative outcomes compared to those who had not previously received chemotherapy. Similarly, patients undergoing surgery at high-volume centers presented comparable perioperative outcomes to those in low-volume centers based on the cut-off of three and 10 cases/year. Still, our findings were mitigated by selection bias. Overall, the number of annual RPLND cases in Germany has decreased over time.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"1333-1341"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144214496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospital variation in treatment for synchronous metastatic esophageal and gastric cancer: A nationwide population-based study in the Netherlands.","authors":"Julie F M Geerts, Pauline A J Vissers, Bianca Mostert, Bas P L Wijnhoven, Brigitte C M Haberkorn, Marie-Paule G F Anten, Camiel Rosman, Geert-Jan Creemers, Harm Westdorp, Maurice J C van der Sangen, Rob H A Verhoeven, Grard A P Nieuwenhuijzen","doi":"10.1002/ijc.35491","DOIUrl":"10.1002/ijc.35491","url":null,"abstract":"<p><p>Care for metastatic esophageal (EC) or gastric cancer (GC) includes a large variety of treatment modalities. Data on treatment variation across centers are unknown. This study investigated treatment variation across hospitals and its effect on overall survival (OS) in the Netherlands by conducting a nationwide retrospective cohort study with population-based data from the Netherlands Cancer Registry. Patients diagnosed with synchronous metastatic EC/GC between 2015 and 2022 were included. Multilevel logistic regression assessed treatment patterns according to hospital of diagnosis. OS was analyzed using Cox regression analysis after categorizing hospitals into tertiles based on their adjusted odds (low/medium/high) for systemic treatment (chemotherapy, targeted therapy, and immunotherapy). Among 8406 EC and 3871 GC patients, the proportion receiving systemic treatment varied substantially: 19.8%-69.6% for EC and 15.8%-81.3% for GC across hospitals. Hospital of diagnosis was significantly associated with the adjusted probability of receiving systemic treatment (p < .0001). Ten out of 78 EC (12.8%) and 7 out of 73 (9.6%) GC hospitals had significantly lower systemic treatment probabilities. EC patients with OS ≥4 months diagnosed at hospitals with lower probabilities had significantly worse OS compared to high-probability hospitals (hazard ratios [HR] 0.87 [0.79-0.95] p = .002). GC patients from low-probability hospitals had significantly worse OS than from medium- (HR 0.86 [0.76-0.96], p = .011) or high-probability hospitals (HR 0.73 [0.64-0.82], p < .0001). In conclusion, this study showed substantial hospital variation in treatment for metastatic EC and GC. Hospital of diagnosis was not only associated with the probability of receiving systemic treatment but also OS. This reflects the challenge of ensuring equal healthcare access.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"1446-1457"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144223856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of outcomes between haploidentical and matched related donors for chronic myelomonocytic leukemia: A multicenter real-world study.","authors":"Yu-Qian Sun, Li-Xin Wu, Yi-Cheng Zhang, Ya-Jing Xu, Xiao-Bing Huang, Bao-Dong Ye, Hai-Long Yuan, Jian-Ying Zhou, Su-Jun Gao, Fang Zhou, Yue Liu, Xian-Min Song, Yu Cai, Xiao-Liang Liu, Yi Luo, Lu-Xin Yang, Jian-Min Yang, Li-Bing Wang, Yu-Hua Li, Rui Huang, Shun-Qing Wang, Ming Zhou, Yu-Jun Dong, Qian Wang, Yi-Mei Feng, Xi Zhang, Xin Du, Wei Ling, Han Zhu, Zun-Min Zhu, Xiang-Li Chen, Shi-Yu Wang, Fan-Kai Meng, Ke-Hong Bi, Ning Huang, Ming Jiang, Ting Niu, Jie Ji, Ding-Ming Wan, Zhi-Lei Bian, Yi Chen, Li Liu, Xue-Qian Yan, Xi Yang, Hai Yi, Xu-Dong Wei, Xin Li, Qian Cheng, Cheng-Lu Yuan, Wen Wang, Yu-Hong Zhou, Yu-Hong Chen, Feng-Rong Wang, Yuan-Yuan Zhang, Zhi-Dong Wang, Xiao-Dong Mo, Wei Han, Jing-Zhi Wang, Yu Wang, Huan Chen, Xiang-Yu Zhao, Ying-Jun Chang, Kai-Yan Liu, Jia Feng, Lan-Ping Xu, Hong-Yu Zhang, Xiao-Jun Huang, Xiao-Hui Zhang","doi":"10.1002/ijc.35485","DOIUrl":"10.1002/ijc.35485","url":null,"abstract":"<p><p>Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative strategy for patients with chronic myelomonocytic leukemia (CMML). However, few reports have investigated the outcomes of patients receiving haploidentical HSCT. To this end, we included 117 patients with haploidentical donors (HID) and 75 patients with matched related donors (MRD) from 28 centers across China to explore the prognostic impact of different transplantation modalities. We found no significant difference between these two groups in terms of event-free survival (EFS, p = .211), overall survival (OS, p = .503), cumulative incidence of relapse (CIR, p = .076) or non-relapse mortality (NRM, p = .794). The predominance of peripheral blood (PB) graft source over bone marrow and PB since 2020 may have contributed to the worse outcomes in the MRD group. Moreover, CMML-specific prognostic scoring system (CPSS) lower-risk patients benefited more from the HID modality with superior EFS (p = .006). Multivariate analysis indicated that advanced age (p = .013), anemia at diagnosis (p = .010), and donor relationship (parent-to-child, p = .013) were independently associated with worse EFS in the HID group. Our data suggested that HID was comparable to MRD in CMML. However, under certain conditions, such as CPSS lower-risk ones, HID was preferred.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"1420-1432"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomised trial on treatment of vaginal high-grade squamous intraepithelial lesion: Self-administered vaginal imiquimod and laser vaporisation.","authors":"Mari Kiviharju, Annika Riska, Ilkka Kalliala, Maija Jakobsson, Annu Heinonen, Joakim Dillner, Pekka Nieminen, Karoliina Aro","doi":"10.1002/ijc.35497","DOIUrl":"10.1002/ijc.35497","url":null,"abstract":"<p><p>High grade vaginal squamous intraepithelial lesion (HSIL) (or vaginal intraepithelial neoplasia; VAIN) is a rare human papillomavirus (HPV)-related cancer precursor, which is commonly treated with laser vaporisation or other surgical methods to prevent progression to invasion. Vaginal HSIL has a substantial tendency to relapse despite treatment, for which HPV persistence is a known risk factor. Imiquimod is a topically applied immunomodulator and has shown promise in the treatment of high-grade HPV-related genital cancer precursors. The aim of this study was to assess the efficacy and patient compliance of self-administered vaginal imiquimod in comparison to laser vaporisation in the treatment of vaginal HSIL. We recruited 56 women with histological vaginal HSIL into a randomised controlled trial of laser vaporisation and self-administered vaginal imiquimod with follow-up up to 6 months. Follow-up visits included colposcopy, punch biopsies, and cervical or vaginal swabs for HPV genotyping. In per protocol analyses of 26 women in the laser arm and 27 women in the imiquimod arm, 53.8% and 77.8% (p = 0.07), respectively, showed histological regression at the end of the study. No progressions to invasion were detected during the study period. Genotype-specific post-treatment negativity for HPV occurred in 16.7% of the laser group and in 39.1% of the imiquimod group (p = 0.12). Imiquimod had short-term adverse effects, but 93% completed treatment as instructed. We conclude that vaginal imiquimod is an effective treatment for vaginal HSIL and could be considered an alternative to laser vaporisation.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"1458-1464"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144197779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients.","authors":"Kathrin Niedermayer, Henning Schäffler, Georgios Vlachos, Sara Greco, Kerstin Pfister, Barbara Volz, Leonie Ott, Hans Neubauer, Bernhard Polzer, André Koch, Sabine Riethdorf, Tanja Fehm, Wolfgang Janni, Thomas W P Friedl, Brigitte Rack, Ellen Heitzer, Fabienne Schochter, Lisa Wiesmüller","doi":"10.1002/ijc.35498","DOIUrl":"10.1002/ijc.35498","url":null,"abstract":"<p><p>Circulating tumor cells (CTCs) can serve as a liquid biopsy to gain insight into treatment responses and metastatic recurrence. Due to their rarity, the analysis of CTCs is challenging and commonly based on immunomagnetic technologies using antibodies against EpCAM. This study used mass cytometry (CyTOF®) for the identification and characterization of CTCs from longitudinally monitored metastatic breast cancer (mBC) patients. Functional analysis focused on DNA damage responses, particularly the DNA repair pathway of homologous recombination (HR) validated in BC cells from the pleura. Fifty-two blood samples from 13 mBC patients were collected for the enumeration of CTCs using CellSearch® technology, isolation of CTCs together with peripheral blood mononuclear cells (PBMCs) and of plasma. Cell-free DNA (cfDNA) from plasma was analyzed by shallow genome sequencing to determine tumor fraction (TF) and HR deficiency (HRD). CTC/PBMC mixtures were phenotyped by CyTOF® using a panel of 13 antibodies including anti-γH2AX, 53BP1, and RAD51. CyTOF® identified CTCs correlating with CellSearch®- and cfDNA-based quantifications, detected DNA damage in CTCs, and the dynamics of their HR status during genotoxic therapies. Our study shows that CyTOF®-based phenotyping of CTCs from mBC patients shows promise as a method to monitor tumor progression and HR proficiency in real time for the identification of chemoresistance.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"1465-1480"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}